[1] BANNISTER K, SACHAU J, BARON R, et al. Neuropathic pain: Mechanism-based therapeutics [J]. Annu Rev Pharmacol Toxicol, 2020, 60:257-274.
[2] SMITH S J, EWAN. Advances in understanding nociception and neuropathic pain [J]. J Neurol, 2018, 265(2):231-238.
[3] HEHN C A V, BARON R, WOOLF C J. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms [J]. Neuron, 2012, 73(4):638-652.
[4] JI R R, NACKLEY A V, HUH Y, et al. Neuroinflammation and central sensitization in chronic and widespread pain [J]. Anesthesiology, 2018, 129(2):343-366.
[5] FINNERUP N B, SINDRUP S H, JENSEN T S. The evidence for pharmacological treatment of neuropathic pain [J]. Pain, 2010, 150(3):573-581.
[6] SAGHEDDU C, MELIS M. Individual differences and vulnerability to drug addiction: a focus on the endocannabinoid system [J]. CNS Neurol Disord Drug Targets, 2015, 14(4):502-517.
[7] HAUSER A S, CHAVALI S, MASUHO I, et al. Pharmacogenomics of GPCR drug targets [J]. Cell, 2018, 172(1-2):41-54.
[8] LAUSCHKE V M, INGELMAN-SUNDBERG M. Prediction of drug response and adverse drug reactions: From twin studies to next generation sequencing [J]. Eur J Pharm Sci, 2019, 130(2019):65-77.
[9] LEE J, YOO H D, BAE J W, et al. Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6 [J]. Drug Des Dev Ther, 2019, 13:1751-1761.
[10] RYU S, PARK S, LEE J H, et al. A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans [J]. CTS Clin Transl Sci, 2017, 10(2):93-101.
[11] HSIAO Y H, HUI R C, WU T, et al. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations [J]. J Dermatol Sci, 2014, 73(2):101-109.
[12] MCCORMACK M, ALFIREVIC A, BOURGEOIS S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans [J]. N Engl J Med, 2011, 364(12):1134-1143.
[13] MILISZEWSKI M A, KIRCHHOF M G, SIKORA S, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: An analysis of triggers and implications for improving prevention [J]. Am J Med, 2016, 129(11):1221-1225.
[14] CHUNG W H, HUNG S I, HONG H S, et al. Medical genetics: a marker for Stevens-Johnson syndrome [J]. Nature, 2004, 428(6982):486. DOI:10.1038/428486a.
[15] HE X J, JIAN L Y, HE X L, et al. Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China [J]. Pharmacol Rep, 2013, 65(5):1256-1262.
[16] CHEN P, LIN J J, LU C S, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan [J]. N Engl J Med, 2011, 364(12):1126-1133.
[17] DEVI K. The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population [J]. Int J Dermatol, 2018, 57(1):70-73.
[18] WANG L B, CHENB, SUN W L, et al. Carbamazepine induced severe epispasis in two patients and their HLA-B*1502 allele detection[J]. Chin Pharm J(中国药学杂志), 2010,45(19):1513-1515.
[19] ZHANG Y, WANG J, ZHAO L M, et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients [J]. Eur J Clin Pharmacol, 2011, 67(9):885-887.
[20] CHANG C C, TOO C L, MURAD S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population[J]. Int J Dermatol, 2011, 50(2):221-224.
[21] TASSANEEYAKUL W, TIAMKAO S, JANTARAROUNGTONG T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population [J]. Epilepsia, 2010, 51(5):926-930.
[22] KHOR A H, LIM K S, TAN C T, et al. HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis [J]. Epilepsia, 2014, 55(11):e120-e124.
[23] ZHOU Y, KREBS K, MILANI L, et al. Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing [J]. Clin Pharmacol Ther, 2021, 109(1):160-174.
[24] KIM S H, LEE K W, SONG W J, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans [J]. Epilepsy Res, 2011, 97(1-2):190-197.
[25] CHOI H, MOHIT B. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States [J]. Epilepsia, 2019, 60(7):1472-1481.
[26] AMSTUTZ U, SHEAR N H, RIEDER M J, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions [J]. Epilepsia, 2014, 55(4):496-506.
[27] OZEKI T, MUSHIRODA T, YOWANG A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population [J]. Hum Mol Genet, 2011, 20(5):1034-1041.
[28] YIP V L, PIRMOHAMED M. The HLA-A*31:01 allele: influence on carbamazepine treatment [J]. Pharmacogenomics Pers Med, 2017, 10:29-38.
[29] PHILLIPS E J, SUKASEM C, WHIRL-CARRILLO M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update clinical pharmacology and therapeutics [J]. Clin Pharmacol Ther, 2018, 103(4):574-581.
[30] AMSTUTZ U, ROSS C J, CASTRO-PASTRANA L I, et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children [J]. Clin Pharmacol Ther, 2013, 94(1):142-149.
[31] ZHOU M, CHEN N, HE L, et al. Oxcarbazepine for neuropathic pain [J]. Cochrane Database Syst Rev, 2017, 12(12):Doi:10.1002/14651858.CD007963.
[32] CHEN M, YANG B, WANG C, et al. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype [J]. Australas J Dermatol, 2016, 57(4):e137-e138.
[33] DUEHMKE R M, DERRY S, WIFFEN P J, et al. Tramadol for neuropathic pain in adults [J]. Cochrane Database Syst Rev, 2017, 6(6):CD003726.
[34] ZEBALA J A, SEARLE S L, WEBSTER L R, et al. Desmetramadol has the safety and analgesic profile of tramadol without its metabolic liabilities: Consecutive randomized, double-blind, placebo-and active comparator-controlled trials [J]. J Pain, 2019, 20(10):1218-1235.
[35] NOFZIGER C, TURNER A J. Pharm var gene focus: CYP2D6 [J]. Clin Pharmacol Ther, 2020, 107(1):154-70.
[36] MIOTTO K, CHO A K, KHALIL M A, et al. Trends in tramadol: Pharmacology, metabolism, and misuse [J]. Anesth Analg, 2017, 124(1):44-51.
[37] SMITH D M, WEITZEL K W, ELSEY A R, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial [J]. Genet Med, 2019, 21(8):1842-1850.
[38] SMITH E C. Understanding CYP2D6 and its role in tamoxifen metabolism [J]. Oncol Nurs Forum, 2013, 40(6):547-548.
[39] MEHRPOUR O. Addiction and seizure ability of tramadol in high-risk patients [J]. Indian J Anaesth, 2013, 57(1):86-87.
[40] NIWA T, YANAI M, MATSUMOTO M, et al. Effect of cytochrome P450 (CYP) 2D6 genetic polymorphism on the inhibitory action of antidepressants on CYP2D6-mediated dopamine formation from p-tyramine [J]. J Pharm Pharm Sci, 2018, 21(1):135-142.
[41] DONG H, LU S J, ZHANG R, et al. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients [J]. Eur J Clin Pharmacol, 2015, 71(6):681-686.
[42] SMITH D M, WEITZEL K W, ELSEY A R, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial [J]. Genet Med, 2019, 21(8):1842-1850.
[43] QI G, YIN S, ZHANG G, et al. Genetic and epigenetic polymorphisms of eNOS and CYP2D6 in mainland Chinese Tibetan, Mongolian, Uygur, and Han populations[J]. pharmacogenomics J, 2020, 20(1):114-125.
[44] KUMAR P, RAI V. Catechol-O-methyltransferase gene Val158Met polymorphism and obsessive compulsive disorder susceptibility: a meta-analysis [J]. Metab Brain Dis, 2020, 35(2):241-251.
[45] TANG Z, ZHANG S, GUO D, et al. Association between COMT gene Val108/158Met and antidepressive treatment response: A meta-analysis [J]. Gene, 2020, 734:144333.
[46] SERRANO J M, BANKS J B, FAGAN T J, et al. The influence of Val158Met COMT on physiological stress responsivity [J]. Stress, 2019, 22(2):276-279.
[47] REN X, ZHANG L, XIAO Q, et al. Association between COMT polymorphism, labor anxiety, and analgesia in pregnant women [J]. J Pain Res, 2019, 12:779-785.
[48] NIELSEN L M, OLESEN A E, SATO H, et al. Association between gene polymorphisms and pain sensitivity assessed in a multi-modal multi-tissue human experimental model-an explorative study [J]. Basic Clin Pharmacol Toxicol, 2016, 119(4):360-366.
[49] HOOTEN W M, BIERNACKA J M, O′BRIEN T G, et al. Associations of catechol-O-methyltransferase (rs4680) single nucleotide polymorphisms with opioid use and dose among adults with chronic pain [J]. Pain, 2019, 160(1):263-268.
[50] ZHANG F, TONG J, HU J, et al. COMT gene haplotypes are closely associated with postoperative fentanyl dose in patients [J]. Anesth Analg, 2015, 120(4):933-940.
[51] CRIST R C, BERRETTINI W H. Pharmacogenetics of OPRM1 [J]. Pharmacol Biochem Behav, 2014, 123:25-33.
[52] ZHANG X, LIANG Y, ZHANG N, et al. The relevance of the OPRM1 118A>G genetic variant for opioid requirement in pain treatment: A meta-analysis [J]. Pain Physician, 2019, 22(4):331-340.
[53] PETTINI E, MICAGLIO M, BITOSSI U, et al. Influence of OPRM1 polymorphism on postoperative pain after intrathecal morphine administration in italian patients undergoing elective cesarean section [J]. Clin J Pain, 2018, 34(2):178-181.
[54] CHEN L K, CHEN S S, HUANG C H, et al. Polymorphism of μ-opioid receptor gene (OPRM1:c.118A>G) might not protect against or enhance morphine-induced nausea or vomiting [J]. Pain Res Treat, 2013, 2013:259306. Doi:10.1155/2013/259306.
[55] LIANG J, LIU X, PAN M, et al. Blockade of Nav1.8 currents in nociceptive trigeminal neurons contributes to anti-trigeminovascular nociceptive effect of amitriptyline [J]. Neuromol Med, 2014, 16(2):308-321.
[56] KOH A, PAK K C, CHOI H Y, et al. Quantitative modeling analysis demonstrates the impact of CYP2C19 and CYP2D6 genetic polymorphisms on the pharmacokinetics of amitriptyline and its metabolite, nortriptyline [J]. J Clin Pharmacol, 2019, 59(4):532-540.
[57] HICKS J K, SANGKUHL K, SWEN J J, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update [J]. Clin Pharmacol Ther, 2017, 102(1):37-44.
[58] SIENKIEWICZ-OLESZKIEWICZ B, WIELA-HOJESKA A. CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs [J]. Pharmazie, 2018, 73(11):619-624.
[59] LI M, ZHOU L J, ZHAN F, et al. Based on CYP2C19 genotype ofclopidogrel and ticagrelortreatment of acute coronary syndromes individualized drug analysis [J]. Chin Pharm J(中国药学杂志), 2019,54(9):753-760.
[60] WEIDE J V D, BAALEN-BENEDEK E H V, KOOTSTRA-ROS J E. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype [J]. Ther Drug Monit, 2005, 27(4):478-483.
[61] PERRY P J, ZEILMANN C, ARNDT S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response [J]. J Clin Psychopharmacol, 1994, 14(4):230-240.
[62] STEIMER W, ZÖPF K, VON AMELUNXEN S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers [J]. Clin Chem, 2004, 50(9):1623-1633.
[63] SHAHEEN A, ALAM S M, AZAM F, et al. Influence of single nucleotide polymorphism of LAT1 on therapeutic response to gabapentinoids in Pakistani patients with neuropathic pain [J]. Basic Clin Pharmacol Toxicol, 2021, 128(3):503-510.
[64] LUNN M P, HUGHES R A, WIFFEN P J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia [J]. Cochrane Database Syst Rev, 2014 (1):Doi:10.1002/14651858.CD007115.pub3.
[65] CHEN J D, XU X Z, CHEN B B. Association of CYP1A2 and CYP2D6 gene polymorphism with therapeutic efficacy of duloxetine on depression in southern region of Fujian[J]. Chin J Behav Med Brain Sci(中华行为医学与脑科学杂志), 2015, 24(12):1090-1093.
[66] PERLIS R H, FIJAL B, ADAMS D H, et al. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder [J]. Biol Psychiatry. 2009, 65(9):785-791.
[67] PILOTTO A, FRANCESCHI M, VITALE D F. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs [J]. Aliment Pharmacol Ther, 2005, 22(2):147-155.
[68] OCHOA D, PRIETO-PÉREZ R, ROMÁN M, et al. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers [J]. Pharmacogenomics, 2015, 16(9):939-948.